All In Biotech

NDA 205677 · Vanda Pharms INC

Hetlioz

Tasimelteon · Oral · Melatonin Receptor Agonist

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jan 31, 2014

Approved uses

2

Original approval plus efficacy supplements

Registered trials

25

12 Phase 3, 2 recruiting

FAERS reports

5,773

600 serious, 166 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 4, 2026.

HETLIOZ is a melatonin receptor agonist. HETLIOZ capsules are indicated for the treatment of: Non-24-Hour Sleep-Wake Disorder (Non-24) in adults ( 1 ) Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older ( 1 ) HETLIOZ LQ oral suspension is indicated for the treatment of: Nighttime sleep disturbances in SMS in pediatric patients 3 years to 15 years of age ( 1 ) 1.1 Non-24-Hour Sleep-Wake Disorder (Non-24) HETLIOZ capsules are indicated for the treatment of Non-24 in adults. 1.2 Nighttime Sleep Disturbances in Smith-Magenis Syndrome (SMS) HETLIOZ capsules are indicated for the treatment of nighttime sleep disturbances in SMS in patients 16 years of age and older. HETLIOZ LQ oral suspension is indicated for the treatment of nighttime sleep disturbances in SMS in pediatric patients 3 to 15 years of age.

Mechanism: The mechanism by which tasimelteon exerts its therapeutic effect in patients with Non-24 or nighttime sleep disturbances in SMS is unclear. However, tasimelteon is an agonist at melatonin MT 1 and MT 2 receptors which are thought to be involved in the control of circadian rhythms.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 1, 2020 Supplement 7 · Efficacy · priority review OrphanLabelLetter
  • Jan 31, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • HETLIOZ · TASIMELTEON 20MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tasimelteon" as an intervention, any sponsor and status, largest first.

All 25 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,636
  • insomnia730
  • product dose omission issue475
  • middle insomnia412
  • somnolence409
  • headache386
  • nightmare268
  • abnormal dreams224
  • fatigue224
  • therapeutic product effect decreased193
  • sleep disorder189
  • inappropriate schedule of product administration185

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20149
2015577
2016408
2017308
2018540
2019776
2020741
2021730
2022550
2023559
2024331
2025150
202694

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Hetlioz (Tasimelteon)

2024 spending

$65.3M

Beneficiaries

304

2,378 claims

Per beneficiary

$214,778

$752.30 per unit

View as table
YearSpending
2020$128,931,589
2021$135,929,136
2022$122,390,230
2023$95,952,401
2024$65,292,431

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Vanda Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.